More Articles

Global guidelines for biosimilars Guidelines | Posted 08/10/2010

Last update: 15 June 2018The public health arm of the United Nations is World Health Organisation (WHO).WHO, via its biological standardisation programme, develops guidelines and recommendatio...

EU guidelines for generics Guidelines | Posted 08/10/2010

Last update: 18 November 2011The regulatory body for approval of medicines of the EU is EMA.When using a centralised procedure, which covers marketing authorisation for the whole of the EU, generic...

EU guidelines for biosimilars Guidelines | Posted 08/10/2010

Last update: 8 January 2016The regulatory body for approval of medicines in the European Union (EU) is the European Medicines Agency (EMA). The agency is responsible for the scientific evaluation o...

Pharmacists could save the NHS GBP 1 billion Reports | Posted 01/10/2010

More than GBP 1 billion could be saved by the National Health Service (NHS) through better use of pharmacists in improving outcomes in public health and long-term conditions, a new report claims.

AstraZeneca expands its generics business with Indian agreements Pharma News | Posted 01/10/2010

In line with its continued mission to supply branded generics to emerging markets, such as Africa and Latin America, AstraZeneca has entered into yet another agreement with an Indian generics firm.

Epoetin alfa and pure red cell aplasia Biosimilars/Research | Posted 01/10/2010

Most therapeutic proteins have the potential to induce an immune response. Cases of pure red cell aplasia (PRCA) were reported after the formulation of Eprex (epoetin alfa) was changed. It is now k...

Incentives to use generic medicines Generics/Research | Posted 01/10/2010

A variety of financial and non-financial incentives are intended to encourage generic prescribing. Physician budgets are used by Germany and UK and seem to encourage generic prescribing. Assistance...

An industry view of generic manufacturing Generics/Research | Posted 01/10/2010

Research and development of innovative medicines are becoming more challenging, with only 29 medicines with new chemical entities launched in 2006. The dwindling pipeline of new innovative medicine...